Delivery Order SPE2DB20D2001-SPE2DB26FPLKF
- Not listed
- The Defense Logistics Agency awarded a $13,916.52 delivery order to AmerisourceBergen Drug Corp for Yupelri 175 mcg/3 ml solution in unit-dose vials on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price, competitively awarded contract (no set-aside used) calls for the pharmaceutical distributor to deliver the medication to its Conshohocken, Pennsylvania location. The award represents a child delivery order under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $2,092.08 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Yupelri 175 mcg/3 mL solution in unit dose vials. The award, issued on October 24, 2025, with an ultimate completion date of October 27, 2025, represents a competitively awarded, non-set-aside contract for pharmaceutical supply. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is...
- The Defense Logistics Agency awarded a $1,973.31 delivery order to AmerisourceBergen Drug Corp for Yupelri 175 mcg/3 mL solution in unit dose 3 mL vials. This is a firm fixed price, competitively awarded contract with no set-aside designation, with an ultimate completion date of August 1, 2025. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a $1,309.59 delivery order to AmerisourceBergen Drug Corp for Yupelri 175 mcg/3 mL solution in unit dose 3 mL vials on September 25, 2025, with completion expected by September 26, 2025. This competitive award utilizes a firm fixed price contract type with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance and is a major pharmaceutical distributor providing critical medical supplies...
- The Defense Logistics Agency awarded a delivery order valued at $12,881.25 to AmerisourceBergen Drug Corp for Yupelri 175 mcg/3 ml solution in unit dose vials on August 14, 2025, with an ultimate completion date of August 15, 2025. This firm fixed-price delivery order represents a pediatric or specialized pharmaceutical supply requirement fulfilled through competitive procurement with no set-aside designation. The place of performance is AmerisourceBergen's Corporate Office location in...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,310.25 for Yupelri 175 mcg/3 ml solution in unit dose 3 ml vials. This is a firm fixed price, competitively awarded contract with no set-aside designation, with an ultimate completion date of August 21, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $1,670.65 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Yupelri 175 mcg/3 mL Solution in unit dose vials. The order, issued on August 18, 2025, with completion targeted for August 19, 2025, represents a pharmaceutical supply delivery supporting federal medical procurement needs. This delivery order is classified as a child contract under AmerisourceBergen's broader federal contracting relationship and involves no set-aside...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $4,309.90 on September 12, 2025, for Yupelri 175 mcg/3 ml solution in unit dose 3 ml vials. This is a firm fixed price, non-set-aside contract with an ultimate completion date of September 15, 2025, and performance taking place at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen is a major pharmaceutical distributor and critical federal medical procurement vendor that serves...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Yupelri 175 mcg/3 mL solution in unit dose 3 mL vials, with a ceiling value of $8,823.72. This non-competitive delivery order was awarded on August 11, 2025, with an ultimate completion date of August 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract employs firm fixed price pricing and represents a routine pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Yupelri (roflumilast) 175 micrograms per 3 milliliters solution in unit dose 3-milliliter vials. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $1,587.44 and is scheduled for completion by August 11, 2025. The contract involves no set-aside designation and reflects AmerisourceBergen's role as a critical pharmaceutical distributor...
- SPE2DB20D2001Indefinite Delivery Contract
- SPE2DB20D2001-SPE2DB26FPLKFDelivery Order
The Defense Logistics Agency awarded a $2,623.02 delivery order to AmerisourceBergen Drug Corp for Yupelri (ipratropium bromide) 175 mcg/3 mL solution in unit dose vials on October 29, 2025, with an ultimate completion date of October 30, 2025. The contract is a firm fixed-price delivery order with no set-aside designation, performed at the contractor's facility in Conshohocken, Pennsylvania. This award represents a competitive procurement through the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is a critical federal vendor for medical procurement serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. As a child delivery order under the SPE2DX prime IDC, this award for respiratory medication exemplifies the company's role in supplying specialty pharmaceuticals and medical commodities across multiple therapeutic domains to support military operations and veteran healthcare needs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.6k | 10/29/25 |